Pharvaris Secures $124M Net from Offering, Extends Cash Runway to 2028, Reports Improved Q1 Loss
Summary
Pharvaris announced the closing of its $124.3 million net proceeds public offering, extending its cash runway into 2028, and reported an improved Q1 2026 net loss while advancing its clinical pipeline.
Key Events
-
Offering Closed
Successfully closed an underwritten public offering, generating approximately $124.3 million in net proceeds.
-
Extended Cash Runway
The capital raise extends the company's cash runway into 2028, funding ongoing R&D and commercialization.
-
Improved Q1 Financials
Reported a net loss of €39.2 million for Q1 2026, an improvement from €46.3 million in Q1 2025.
-
Clinical Milestones On Track
NDA submission for deucrictibant IR (on-demand HAE) remains on track for 1H2026, and topline data from the CHAPTER-3 study (prophylactic HAE) is expected in 3Q2026.
Analysis
This filing confirms the successful closing of a significant public offering, providing $124.3 million in net proceeds. Crucially, this capital raise extends the company's cash runway into 2028, significantly de-risking its operations and funding its late-stage clinical programs and commercialization efforts. The Q1 2026 financial results also show an improved net loss compared to the prior year, alongside continued progress in its key HAE and AAE clinical trials, including an NDA submission on track for 1H2026 and topline data expected in 3Q2026.
At the time of this filing, PHVS was trading at $32.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.59 to $31.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.